Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 665-669

  Beaulac, Christian ^a   Clément Major, Sébastien ^a   Hawari, Jalal ^b   Lagacé, Jacqueline ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SCREENING; DRUG TISSUE LEVEL; ENCAPSULATION; INTRATRACHEAL DRUG ADMINISTRATION; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; COLONY COUNT, MICROBIAL; LIPOSOMES; LUNG; LUNG DISEASES; MUCOUS MEMBRANE; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION; TOBRAMYCIN;

EID: 0030048689     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.665     Document Type: Article

References (45)

1. Anwar, H., T. Van Biesen, M. Dasgupta, K. Lam, and J. W. Costerton. 1989. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system Antimicrob. Agents Chemother 33:1824-1826.
2. Assil, K. K., J. Frucht-Perry, E. Ziegler, D. J. Schanzlin, T. Schneiderman, and R. N. Weinred. 1991. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Invest. Ophthalmol Visual Sci. 32:3216-3220
3. Barends, D. M., J. S. F. Van Der Sandt, and A. Hulshoff. 1980. Microdetermination of gentamicin in serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 183:201-210.
4. Barends, D. M., C. L. Zwaan, and A. Hulshoff. 1981 Microdetermination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 225:417-426.
5. Barends, D. M., C. L. Zwaan, and A. Hulshoff. 1981. Improved microdetermination of gentamycin and sisomicin in serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 222:316-323.
6. Bayer, A. S., J. Peters, T. R. Parr, Jr., L. Chan, and R. E. W. Hancock. 1987. Role of β-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother. 31:253-258.
7. Beaulac, C., S. Clement-Major, J. Hawari, and J. Lagacé. "In vitro" kinetics of drug release and pulmonary retention of encapsulated antibiotic in liposomal formulations in relation to the lipid composition of liposomes. Submitted for publication.
8. Bryant, R. E., and D. Hammond. 1974. Interaction of purulent material with antibiotics used to treat Pseudomonas, aeruginosa. Antimicrob. Agents Chemother 6:702-707.
9. Campbell, M. E., S. W. Farmer, and D. P. Speert. 1988. New selective medium for Pseudomonas aeruginosa with phenanthroline and 9-chloro-9-[4-(diethylamino)phenyl]-9,10-dihydro-10-phenylacridine hydrochloride (C-390). J. Clin. Microbiol. 26:1910-1913.
10. Costerton, J. W., J. Lam, K. Lam, and R. Chan. 1983. The role of the microcolony in the pathogenesis of Pseudomonas aeruginosa. Rev. Infect. Dis. 5:S867-S873.
11. Crommelin, D. J. A. 1984. Influence of lipid composition and ionic strength on the physical stability of liposomes. J. Pharm. Sci. 73:1559-1562.
12. Dahlberg, A. E., F. Horodyski, and P. Keller. 1978. Interaction of neomycin with ribosomes and ribosomal ribonucleic acid. Antimicrob. Agents Chemother. 13:331-339.
13. Deretic, V., J. F. Gill, and A. M. Charkrabarty. 1987. Alginate biosynthesis. a model system for gene regulation and function in Pseudomonas Bio/ Technology 5:469-477.
14. Drusano, G. L. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297.
15. Fee, W. E., V. Vierra, and D. R. Lathrop. 1978 Clinical evaluation of aminoglycoside toxicity tobramycin vs gentamycin: a preliminary report. J. Antimicrob, Agents Chemother 45:31-36.
16. Fountain, M. W., S. J. Weiss. A. G. Fountain, A. Shen, and R. P. Lenk. 1985. Treatment of Brucella canais and Brucella abortus in vitro and in vivo by stable pleurilamellar vesicles encapsulated aminoglycoside. J. Infect. Dis. 152:529-536.
17. Frères, J. M. 1989. Quantitative relationship between sensitivity to β-lactam antibiotics and β-lactamase production in gram-negative bacteria I. Steadystate treatment. Biochem. Pharmacol. 38:1415-1426.
18. Govan, J. R. W. 1988. Alginate biosynthesis and other unusual characteristics associated with the pathogenesis of Pseudomonas aeruginosa in cystic fibrosis, p. 67-96. In E. Griffiths, W. Donachie, and J. Stephen (ed), Bacterial infections of respiratory and gastrointestinal mucosae. IRL Press, Oxford.
19. Govan, J. R. W., and J. W. Nelson. 1993. Microbiology of cystic fibrosis lung infections: themes and issues. J. R Soc. Med. 86(Suppl. 20):11-18.
20. Grit, M., and D. J. A. Crommelin. 1993. Chemical stability of liposomes: implications for their physical stability. Chem. Phys. Lipids 64:3-18
21. Hodson, M. E. 1988. Antibiotic treatment: aerosol therapy. Chest 94:156S-160S.
22. Hoiby, N., E. W. Flensborg, B. Beck, B. Friis, S. Jacobsen, and L. Jacobsen. 1977. Pseudomonas aeruginosa infection in cystic fibrosis. Scand. J. Respir. Dis. 58:65-79.
23. Hoiby, N., B. Friis. K. Jensen, C. Koch, N. E. Moller, S. Stovring, and M. Szaff. 1982. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr. Scand. Suppl. 301:75-100.
24. Iglewski, B. H., L. Rust, and R. A. Beever. 1990. Molecular analysis of Pseudomonas aeruginosa elastase, p. 36-43. In S. Silver, A. M. Chakrabarty, B. Iglewski, and S. Kaplan (ed.), Pseudomonas: biotransformations, pathogenesis. and evolving biotechnology. American Society for Microbiology, Washington, D.C.
25. Kirby, C., and G. Gregoriadis, 1984. Dehydratation-rehydratation vesicles: a simple method for high yield drug entrapment in liposomes. Bio/Technology 2:979-983.
26. Koch, A. L. 1981. Growth measurement, p. 179-185. In P. Gerhardt, R. G. E. Murray, R. N. Costilow, E. W Nester, W. A. Wood, N. R. Krieg, and G. B. Phillips (ed.), Manual of methods for general bacteriology. American Society for Microbiology. Washington, D.C.
27. Lagace, J., M. Dubreuil, and S. Montplaisir. 1991. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa. J. Microencapsulation 8:53-61.
28. Lam, J., R. Chan, K. Lam, and J. W. Costerton. 1980. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28:546-556.
29. Levy, J., A. L. Smith, M. A. Kenny, B. Ramsey, and F. D. Schoenknecht. 1983. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. I nfect. Dis. 148:1069-1076.
30. May, T. B., D. Shinabarger, R. Maharaj, J. Kato, L. Chu, J. D. DeVault, S. Roychoudhury, N. A. Zielinski, A. Berry, R. K. Rothmel, T. K. Misra, and A. M. Chakrabarty. 1991 Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin. Microbiol. Rev. 4:191-206.
31. Mendelman, P. M., A. L. Smith, J. Levy, A. Weber, B. Ramsey, and R. L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum Am. Rev Respir. Dis 132:761-765
32. Nicas, T. L, and B. H. Iglewski. 1985. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can. J. Microbiol. 31:387-392
33. Nickel, J. C., I. Ruseska, J. B. Wright, and J. W. Costerton. 1985. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob. Agents Chemother. 27:619-624.
34. Nikaido, H. 1989. Role of the outer membrane of gram-negative bacteria in antimicrobial resistance, p. 1-34. In L E Bryan (ed.), Handbook of experimental pharmacology, vol. 91. Microbiobial resistance to drugs. Springer-Verlag KG. Berlin.
35. Nikaido, H., and S. Normark. 1987. Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: a quantitative predictive treatment. Mol Microbiol. 1:29-36.
36. Omri, A., C. Beaulac, M. Bouhajib, S. Montplaisir, M. Sharkawi, and J. Lagacé. 1994 Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38: 1090-1095.
37. Pier, G. B, 1986. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis. current status of the host-bacterium interaction. J. Infect. Dis. 151:575-580.
38. Potter, J. L., L. W. Matthews, S. Spector, and J. Lemm. 1965 Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics 36:714-720.
39. Price, C. I., J. W. Horton, and C. R. Baxter. 1992. Liposomes: a new method for the delivery of burn wounds antimicrobial therapy. Surg. Gynecol Obstet 174:175-182.
40. Price, C. I., J. W. Horton, and C. R. Baxter. 1994. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery 115: 480-487.
41. Schentag, J. J., T. J. Cumbo, W. J. Jusko, and M. E. Plant. 1978. Gentamycin tissue accumulation and nephrotoxic reactions JAMA 240:2067-2069.
42. Smith, C. R., P. R. Maxwell, C. O. Edwards, J. F. Rogers, and P. S. Lietman. 1988. Nephrotoxicity induced by gentamycin and amikacin Johns Hopkins Med. J. 142:85-90
43. Vasil, M. L. 1986. Pseudomonas aeruginosa: biology, mechanism of virulence, epidemiology. J. Pcdiatr 108:800-805.
44. Yoneyama, H., A. Akatsuka, and T. Nakae. 1986. The outer membrane of Pseudomonas aeruginosa is a barrier against the penetration of disaccharides. Biochem. Biophys. Res. Commun. 134:106-112.
45. Zach, M. S. 1988. Antibiotic aerosol treatment. Chest 94:160S-162S.